Back to Awarded Treatment Trials


Awarded Trial: 03T-483

Grant ID

03T-483

Illness

Schizophrenia

Primary Drug/Intervention

D-Serine

Primary Dosage

up to 2g/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Weiser

Sample Size

200

Duration of Study Period for Each Subject

16 weeks

Outcome Measurements

PANSS, SANS, BPRS, CGI, movement disorder scales

Results

195 patients were randomized and 149 completed the trial. There were no significant differences between d-serine and controls on PANSS positive or negative symptoms or on cognitive function as assessed by the MATRICS.

Publication

D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology. 2013 Feb;38(3):492-503.

Link

http://www.ncbi.nlm.nih.gov/pubmed/23093223

PI Name

Mark Weiser

Degree

MD

Center

Sheba Medical Center

Institution

Psychiatric Outpatient Clinic

Address

Sheba Medical Center

City or Town

Tel Hashomer

State or Province

N/A

Zip or Postal Code

52621

Country

Israel

Email Address

mweiser@netvision.net.il